A review of the articles you found most interesting this year.
The company will invest €13 million in the facility, which will make drug-coated balloons for peripheral artery disease.
Meaningful data integration and patient empowerment are driving next-generation diabetes technology.
The company’s Bakken Research Centre in the Netherlands is centrally located for technology development and collaboration with physicians.
There is no such thing as minimum or maximum compliance—there is just compliance.
Medtronic repeatedly fails to correct manufacturing violations related to its Synchromed II Implantable Infusion Pump Systems.
IBM’s Watson Health Unit is forming several collaborations to facilitate personalized health on a massive scale.
The company’s heart devices such as implantable defibrillators, artificial valves and devices to treat atrial fibrillation, contributed to a 5 percent increase in sales in the cardiac and vascular business, its largest unit.
Medtronic has completed the 50 billion acquisition of Covidien, in the largest medical device merger of all time.
According to a regulatory filing dated January 12, Medtronic and Covidien could complete their $43 billion mega-merger by the end of the month.